Clinical trial NCT00503867: SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
Official title: A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Carcinoma, Hepatocellular
Hepatoma
Keywords: unresectable hepatocellular carcinoma
HCC
SIR-Spheres
Y-90 Microspheres
brachytherapy
Selective Internal Radiation Therapy (SIRT)
liver cancer
Lead sponsor: Sirtex Medical
Sponsor class: INDUSTRY
First posted: 2007-07-19
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to determine the safety and toxicity of treatment with SIR-Spheres® in patients with unresectable primary liver cancer or hepatocellular carcinoma (HCC). Other purposes of this study include assessment of the effect of treatment on overall survival, the length of time it takes for the disease to worsen, if and how the treatment affects the patient's quality of life, and if and how the cancer responds to the treatment.

Detailed description: This study is a multi-institutional, non-randomized pilot study that aims to assess the safety and toxicity of hepatic arterial radioembolization using SIR-Spheres yttrium-90 microspheres (SIR-Spheres microspheres) in the treatment of patients with unresectable primary hepatocellular carcinoma (HCC). The study aims to recruit 40 patients over a period of 24 months.

Eligibility criteria: Inclusion Criteria:

* must have a confirmed diagnosis of HCC.
* at least 18 years of age.
* must have a confirmed diagnosis of HCC either by histological confirmation or, in a subject who exhibits a vascular liver mass in the presence of radiographically apparent cirrhosis, an alpha-fetoprotein (AFP) level greater than 500 International Units/milliliter (UI/ml).
* must present HCC that is not amenable to surgical resection or immediate liver transplantation, or that is not optimally treatable with local ablative techniques such as radio-frequency ablation due to its size, extent or presence of cirrhosis.
* must present measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as greater than or equal to 10 mm with spiral CT scan or greater than or equal to 20 mm using conventional techniques (CT, MRI).
* must present with a whole-liver tumor burden of greater than or equal to 15% and less than or equal to 70%
* must have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.
* must have normal organ and marrow function

Exclusion criteria:

Includes both the listed contraindications to SIR-Spheres® and the exclusion criteria specific to the setting of this investigational study:

* hepatic artery directed therapy within the previous 6 months.
* chemotherapy within the previous 4 weeks
* have not recovered from adverse events due to agents administered previously
* Prior external hepatic radiation therapy for HCC, more than two prior systemic chemotherapy regimes for HCC or any other concomitant therapy for HCC
* Currently receiving any other investigational agents for the treatment of their cancer.
* Any extra-hepatic metastases other than metastatic disease found in the lung, bone and/or abdominal lymph nodes that are not otherwise life limiting.
* Any other concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least five years.
* Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
* Any of the following contraindications to angiography and selective visceral catheterization:

  * Bleeding diathesis
  * Severe peripheral vascular disease
  * Portal hypertension with hepatofugal flow
* Female subjects who are pregnant or currently breastfeeding.
* Refusal or inability to use effective means of contraception in men or women of childbearing potential.
* Current enrollment in any other investigational drug or device study.

Primary outcomes:
measure: Number of Participants With Adverse Events Grade 3 or Higher
timeFrame: From date of enrollment until the date of death from any cause assessed up 24 weeks.
Secondary outcomes:
measure: Time to Disease Progression
timeFrame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.
measure: Tumor Response Rate
timeFrame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.
measure: Change From Baseline in Health-related Quality of Life
timeFrame: 52 weeks
measure: Overall Survival
timeFrame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Thomas Jefferson University - Kimmel Cancer Center
state: Pennsylvania
city: Pittsburgh
country: United States
facility: UPMC Liver Cancer Center
state: Pennsylvania
city: Dallas
country: United States
facility: The Liver Institute at Methodist Dallas
state: Texas
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Ravi Murthy, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: UPMC Liver Cancer Center
name: T. Clark Gamblin, MD
role: PRINCIPAL_INVESTIGATOR
References: